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Abstract
Background: Pre-eclampsia/eclampsia are leading causes of maternal mortality and morbidity, particularly in low- and
middle- income countries (LMICs). We developed the miniPIERS risk prediction model to provide a simple, evidence-based
tool to identify pregnant women in LMICs at increased risk of death or major hypertensive-related complications.
Methods and Findings: From 1 July 2008 to 31 March 2012, in five LMICs, data were collected prospectively on 2,081
women with any hypertensive disorder of pregnancy admitted to a participating centre. Candidate predictors collected
within 24 hours of admission were entered into a step-wise backward elimination logistic regression model to predict a
composite adverse maternal outcome within 48 hours of admission. Model internal validation was accomplished by
bootstrapping and external validation was completed using data from 1,300 women in the Pre-eclampsia Integrated
Estimate of RiSk (fullPIERS) dataset. Predictive performance was assessed for calibration, discrimination, and stratification
capacity. The final miniPIERS model included: parity (nulliparous versus multiparous); gestational age on admission;
headache/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic blood pressure; and
dipstick proteinuria. The miniPIERS model was well-calibrated and had an area under the receiver operating characteristic
curve (AUC ROC) of 0.768 (95% CI 0.735–0.801) with an average optimism of 0.037. External validation AUC ROC was 0.713
(95% CI 0.658–0.768). A predicted probability $25% to define a positive test classified women with 85.5% accuracy.
Limitations of this study include the composite outcome and the broad inclusion criteria of any hypertensive disorder of
pregnancy. This broad approach was used to optimize model generalizability.
Conclusions: The miniPIERS model shows reasonable ability to identify women at increased risk of adverse maternal
outcomes associated with the hypertensive disorders of pregnancy. It could be used in LMICs to identify women who would
benefit most from interventions such as magnesium sulphate, antihypertensives, or transportation to a higher level of care.
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Citation: Payne BA, Hutcheon JA, Ansermino JM, Hall DR, Bhutta ZA, et al. (2014) A Risk Prediction Model for the Assessment and Triage of Women with
Hypertensive Disorders of Pregnancy in Low-Resourced Settings: The miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Multi-country Prospective Cohort
Study. PLoS Med 11(1): e1001589. doi:10.1371/journal.pmed.1001589
Academic Editor: Joy E. Lawn, Maternal Reproductive & Child Health, London School of Hygiene & Tropical Medicine, United Kingdom
Received September 3, 2013; Accepted December 4, 2013; Published January 21, 2014
Copyright:  2014 Payne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funders for the study are: The Bill & Melinda Gates Foundation; UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development, and
Research Training in Human Reproduction; Canadian Institutes of Health Research; Preeclampsia Foundation; the Rockefeller Foundation; United States Agency
for International Development; the International Federation of Gynecology and Obstetrics; and the Child and Family Research Institute. The sponsors of the study
had no role in study design, data collection, data analysis or interpretation, but did review this report prior to submission for publication. The corresponding
PLOS Medicine | www.plosmedicine.org 1 January 2014 | Volume 11 | Issue 1 | e1001589
author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Competing Interests: PVD is a paid consultant of Alere International for work not related to the current manuscript; JMA is a founder of a startup company
(LGTMedical) that is attempting to commercialize the development of a cell phone-based pulse oximeter; JMA holds ,5% equity stake in the company. ZAB is a
member of the Editorial Board of PLOS Medicine. No other authors have any conflicts to declare.
Abbreviations: AUC ROC, area under the receiver operating characteristic curve; BP, blood pressure; HDP, hypertensive disorders of pregnancy; HELLP, haemolysis,
elevated liver enzymes, and low platelets; LMIC, low- and middle- income country; LR, likelihood ratio; PIERS, Pre-eclampsia Integrated Estimate of RiSk.
* E-mail: bpayne@cw.bc.ca
{ Deceased.
" Other members of the miniPIERS Study Working Group are listed in the Acknowlegments.
Introduction
The hypertensive disorders of pregnancy (HDP), and in particular
pre-eclampsia and eclampsia, remain one of the top three causes of
maternal mortality and morbidity, globally [1–4]. Pre-eclampsia also
increases fetal risks, having been found to be associated with increased
risk of stillbirth, neonatal death, intrauterine growth restriction, and
preterm birth [4]. The majority of deaths associated with HDP occur
in the low- and middle- income countries (LMICs) in the absence of a
trained health professional [5,6]. The increased burden of adverse
outcomes in LMICs is believed to be due primarily to delays in triage
(identification of who is, or may become, severely ill and should seek a
higher level of care), transport (getting women to appropriate care), and
treatment (provision of appropriate treatment such as magnesium
sulphate, antihypertensives, and timed delivery) [7–9]. A major
contributing factor to the morbidity and mortality associated with
pre-eclampsia is the shortage of health workers adequately trained in
the detection and triage of suspected cases [9].
One method suggested for enhancing outcomes in LMICs is task-
shifting aspects of antenatal care to existing cadres of mid-level health
workers [5,10]. To do this effectively, these health workers require
simple, evidence-based tools for monitoring pregnant women and
accurately identifying who is at greatest risk of severe complications. By
identifying those women at highest risk of adverse maternal outcomes
well before that outcome occurs, transportation and treatment can be
targeted to those women most in need.
Our group has previously developed the Pre-eclampsia
Integrated Estimate of RiSk (fullPIERS) clinical prediction model,
which predicts adverse maternal outcomes among women with
pre-eclampsia on the basis of a woman’s gestational age at
diagnosis, the symptom complex of chest pain and/or dyspnoea,
oxygen saturation by pulse oximetry, and laboratory results of
platelet count, serum creatinine, and aspartate transaminase. The
fullPIERS model, validated in a high-income tertiary hospital
setting, has excellent discriminatory ability with an area under the
receiver operating characteristic curve (AUC ROC) of 0?88 (95%
CI 0?84–0?92) [11]. However, due to the inclusion of laboratory
tests, the fullPIERS model may not be suitable for all settings,
particularly primary care settings in LMICs.
The objective of the miniPIERS study was to develop and
validate a simplified clinical prediction model for adverse maternal
outcomes among women with HDP for use in community and
primary health care facilities in LMICs.
Methods
Study Design and Population
The miniPIERS model was developed and validated on a
prospective, multicentre cohort of women admitted to a partici-
pating centre with an HDP. Participating institutions were: the
Colonial War Memorial Hospital, Suva, Fiji; Mulago Hospital,
Kampala, Uganda; Tygerberg Hospital, Cape Town, South
Africa; Maternidade Escola de Vila Nova Cachoeirinha, Sa˜o
Paulo, Brazil; Aga Khan University Hospital and its secondary
level hospitals at Garden, Karimabad and Kharadar and Jinnah
Post-graduate Medical College, Karachi, Pakistan; and Aga Khan
Maternity & Child Care Centre, and Liaqat University of Medical
Sciences, Hyderabad, Pakistan. Ethics approval for this study was
obtained from each participating institution’s research ethics
board as well as the clinical research ethics board at the University
of British Columbia. All participating institutions had a hospital
policy of expectant management for women with pre-eclampsia
remote from term, and similar guidelines for treatment of women
with regard to magnesium sulphate and antihypertensive agents.
Institutions were chosen to participate on the basis of the
consistency of these guidelines in order to achieve some level of
homogeneity within the cohort and to reduce systematic bias that
could result from differences in disease-modifying practices
between institutions.
Women were admitted to the study with any HDP defined as
follows: pre-eclampsia, defined as (i) blood pressure (BP) $140/
90 mmHg (at least one component, twice, $4 and up to 24 hours
apart, after 20 weeks) and either proteinuria (of $2+ by dipstick,
$300 mg/d by 24 hour collection, or $30 g/mol by urinary
protein:creatinine ratio) or hyperuricaemia (greater than local
upper limit of local non-pregnancy normal range); (ii) haemolysis,
elevated liver enzymes, and low platelets (HELLP) syndrome even
in the absence of hypertension or proteinuria [1]; or (iii)
superimposed pre-eclampsia (clinician-defined rapid increase in
requirement for antihypertensives, systolic BP [sBP] $170 mmHg
or diastolic BP [dBP] $120 mmHg, new proteinuria, or new
hyperuricaemia in a woman with chronic hypertension); or an
‘‘other’’ HDP defined as: (i) gestational hypertension (BP$140/
90 mmHg [at least one component, twice, $4 hours apart, $20+0
weeks] without significant proteinuria); (ii) chronic hypertension
(BP$140/90 mmHg before 20+0 weeks’ gestation); or (iii) partial
HELLP (i.e., haemolysis and low platelets OR low platelets and
elevated liver enzymes). All women participating in the study gave
informed consent according to local ethics board requirements.
Women were excluded from the study if they were admitted in
spontaneous labour, experienced any component of the adverse
maternal outcome before eligibility or collection of predictor
variables, or had confirmed positive HIV/AIDS status with CD4
count ,250 cells/ml or AIDS-defining illness.
Candidate predictor variables for final model development were
identified a priori as being those variables that: (i) would be
available and easy to collect in all health care settings including the
woman’s home; (ii) have been shown to be associated with pre-
eclampsia in previous studies [12]; and (iii) would be measurable
using simple and reliable methods. These variables included
demographics (maternal age, parity, and gestational age on
admission); symptoms (headache, visual disturbances, chest pain/
dyspnoea, right upper quadrant pain or epigastric pain, nausea,
vomiting, and vaginal bleeding with abdominal pain); and signs
(blood pressure and dipstick proteinuria). The values for these
variables were collected prospectively from the woman’s medical
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record as measured by the nurse or physician during regular
antenatal, intrapartum, or postnatal care. If multiple measures of a
candidate predictor were collected within the first 24 hours of
admission, the worst predictor value obtained within that first
24 hours of admission was used. The value used was the worst in
the clinical context, this could either be the highest or lowest value
collected in the given 24 hour time period, depending on the
measure in question. This method of using the worst value was
chosen as it is consistent with clinical practice. Generally, clinicians
will respond to the worst clinical value when making management
decisions.
The components of the composite adverse maternal outcome to
be predicted by the model were determined by Delphi consensus
[13] and include maternal mortality or one or more of serious
central nervous system, cardiorespiratory, renal, hepatic, haema-
tological, or other morbidity. The Delphi consensus process
involved iterative review and feedback on the proposed outcome
components from an expert group consisting of researchers and
clinicians from both high- and low- or middle- income countries
who have published work focused on HDPs. Representatives of
the Delphi group brought expertise from medicine, obstetrics,
pediatrics, anaesthesia, and critical care with sub-specialty
expertise in maternal-fetal medicine, nephrology, haematology,
and placental biology. Data were collected on the occurrence of all
outcome components at any time during admission but for the
purpose of the model, only those that occurred within 48 hours of
admission were considered. All study sites were instructed to
collect information on any ‘‘other’’ adverse events the woman
experienced during pregnancy or immediately postpartum as part
of the regular data collection process. This was done to ensure
balanced reporting of events across all sites. Any reported ‘‘other’’
events were adjudicated by the study Working Group during
regular meetings, at which time the decision was made whether to
include the reported outcome as a study outcome, or not.
A full description of data collected can be found on the study
website (http://pre-empt.cfri.ca/OBJECTIVES/miniPIERS/
Reference.aspx) and definitions of the adverse maternal outcome
components are provided in Table S1.
The external validation study was performed using data from
the fullPIERS [11] dataset. The fullPIERS study was performed to
develop and validate a prediction model for assessing risk in
women with confirmed diagnoses of pre-eclampsia in high-
resourced settings. This model includes gestational age at
admission, chest pain/dyspnoea, oxygen saturation, platelet count,
creatinine, and aspartate aminotransferase. Participating centres
were tertiary academic hospitals located in Canada (six), the UK
(two), New Zealand (one), and Australia (one). Only the fullPIERS
data collected after 1 March 2008 were used for this study as this
portion of the fullPIERS cohort was collected using the same
protocol, inclusion and exclusion criteria, and data collection tools
as later used for miniPIERS. Prior to this date, the fullPIERS
cohort did not include abdominal pain, vaginal bleeding, or any
headache.
Any researcher interested in accessing the miniPIERS or
fullPIERS data can do so through the Pre-eclampsia CoLaboratory
(http://pre-empt.cfri.ca/OBJECTIVES/CoLaboratory.aspx). A
summarized version of the study dataset is also available as
supplementary Dataset S1.
Data Quality and Missing Data
Data for the miniPIERS dataset were collected prospectively
using standardized data collection forms and protocols for all sites
and entered into a customized Microsoft Access database. As part
of the study protocol, women were required to have at least one
measure of proteinuria, blood pressure, and symptoms during the
first 24 hours of admission. All data were reviewed for quality and
consistency. When questions arose regarding data, these data were
confirmed by re-review of the primary health record. Random
review of 10% of cases was performed during the first year of the
study to ensure data validity within and between study sites.
The sample size required for model development was deter-
mined on the basis of the minimum standard of ten events per
effective variable considered in the model according to the formula
N= (n610)/I where N is the sample size, n is the number of
candidate predictor variables, and I is the estimated event rate in
the population [14]. An estimated event rate of 15% based on our
pilot data was used; for a model with 15 effective candidate
predictor variables (i.e., dipstick proteinuria is counted three times
to reflect inclusion of three indicator variables), the sample size
required was 1,000 women [15,16]. This sample size target was
doubled to allow for subgroup analysis at the conclusion of the
study after the finding of confounding by centre during the interim
analysis.
Statistical Methods
Coding of predictors. The relationship between each
predictor variable and the combined adverse maternal outcome
was first assessed by univariate logistic regression. Continuous
variables were assessed for non-linearity, and were modeled as
restricted cubic splines when appropriate [14]. Variables with a
skewed distribution were log-transformed (natural log). Inclusion
of the transformed variable in the final model was based on
comparison to a model with the linear variable and selection of the
model with the lowest Akaike information criterion (AIC) was
automated during the model development process.
To avoid co-linearity, correlation between variables was
determined and only the more clinically relevant variable of a
pair of highly correlated variables was retained. When a high
degree of correlation existed between two symptoms (r.0.5) they
were re-coded as a combined indicator variable.
Model building. Stepwise backward elimination was used
to build the most parsimonious model with a stopping rule of
p,0?20. No interaction terms were included in the model as no
interaction was hypothesized between candidate predictors prior
to analysis.
We assessed the potential for confounding by study site by
examining the bivariate association of study site with predictor
variables and with outcome rate. Dummy (indicator) variables for
study site were included in the model to eliminate confounding of
the predictor-adverse outcome relationship by study site. To make
the final model generalizable to all study settings, the coefficients
for site variables were excluded from the calculation of predicted
probability, and the model’s intercept was adjusted using
previously published methods for updating a prediction model
for a new setting [14].
Assessing the model’s performance. Calibration ability of
the model was assessed visually by plotting deciles of predicted
probability of an adverse maternal outcome against the observed
rate in each decile and fitting a smooth line [14,17]. Discrimina-
tion ability was evaluated on the basis of AUC ROC [18]. The
sensitivity, specificity, positive predictive value, negative predictive
value, and likelihood ratios (LRs) of cut-offs for a positive test
defined using the population within each risk group were
calculated [19]. The following categories for interpretation of the
LRs were used: informative (LR,0?1 or .10); moderately
informative (LR 0?1–0?2 or 5–10); and non-informative (LR
0?2–5).
miniPIERS: HDP Risk Assessment Model for LMICs
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A risk stratification table was generated to assess the extent to
which the model’s predictions divided the population into
clinically distinct risk categories [20].
Model validation. Internal validation of the model was
assessed using 500 iterations each of Efron’s enhanced bootstrap
method [21]. Details of this approach have been described
previously [11,14]. The bootstrapping procedure involved (i)
sampling with replacement from the original cohort to generate a
bootstrap dataset of 2,081 women; (ii) redevelopment of the
model including all model development steps; variable coding
(transformations and categorizations), variable selection, and
parameter estimation in the bootstrapped sample; (iii) estimation
of the AUC ROC for the model in the bootstrap sample; (iv)
application of this new model to the original dataset and
estimation of AUC ROC. Model optimism is then calculated as
the average difference between model performance in the
bootstrap sample and the original dataset after 500 iterations of
this procedure. The choice was made to use 500 iterations
because previous studies have shown no benefit is achieved when
using a higher number of repetitions [16]. A final assessment of
calibration was performed using the Hosmer-Lemeshow goodness
-of-fit test.
A final assessment of model validity was performed by applying
the miniPIERS model to the fullPIERS dataset and estimating the
AUC ROC. Due to the marked difference in underlying rate of
outcomes in the fullPIERS population (6.5% in fullPIERS versus
12.5% in miniPIERS), the model intercept (i.e., the baseline rate)
was adjusted before estimating predictive performance [14]. This
difference in outcome rate between the two cohorts is due to the
difference in setting in which the data was collected, as noted in
the description of the cohorts above, fullPIERS was completed in
high-income country facilities only.
Sensitivity analyses were performed to assess the generalizability
of the model in various subsets of study data. In addition,
sensitivity analyses were performed excluding the most common
components of the adverse maternal outcome to ensure that model
discriminatory ability was maintained. Generalizability of the
model across study regions was further assessed based on the AUC
ROC calculated for the model when applied to each region’s
subset of the total miniPIERS cohort.
All statistical analyses were performed using STATA v11?0
(StataCorp).
Results
From 1 July 2008 to 31 March 2012, 2,133 women were
recruited to the miniPIERS cohort. Fifty-two of these women were
excluded prior to analysis after review of their medical record
revealed that they were ineligible. Medical chart review was able
to resolve all instances of missing predictor variables in the total
cohort. Data relating to the remaining 2,081 women were
included in the model development and internal validation
process. Compared with women who did not have an adverse
outcome, women who had an adverse outcome were more likely to
be nuliparous, to be admitted earlier in gestation, to be admitted
with a diagnosis of pre-eclampsia, to have worse clinical measures
in the first 24 hours of admission, and to have received
corticosteroids and magnesium sulphate, but less likely to have
been delivered by cesarean section (Table 1).
Maternal adverse outcomes included two maternal deaths
during the study. The most common morbidities to occur were
need for blood transfusion (174 women [8?4%]), placental
abruption (70 women [3?4%]), and pulmonary oedema (51
women [2?5%]) (Table 2). There were 32 (1?5%) women with
one or more seizures of eclampsia after admission, of whom 31
received magnesium sulphate.
There was a strong correlation (r.0?5) between the symptoms
of chest pain and dyspnoea, and headache and visual disturbances.
Therefore, these symptoms were re-coded as combined indicator
variables and entered accordingly into the multivariate model. As
expected, systolic and diastolic blood pressure were highly
correlated. Systolic blood pressure was selected for final model
development because it is easier for minimally trained health care
providers to measure by radial artery palpation than detection of
Korotokoff sounds and it has been shown to be reflective of stroke
risk in women with pre-eclampsia [22]. Systolic blood pressure
measurements were log transformed for final model development
as was gestational age at admission due to the highly skewed
distribution of both variables.
Table 3 presents results of the univariate and multivariate
analysis of miniPIERS predictors. The final miniPIERS equation
was: logit (logarithm of the odds)(pi) =25.77+[22.98610216
indicator for multiparity]+[(21.07)6log gestational age at
admission]+[1?346log systolic blood pressure]+[(22?186
1021)6indicator for 2 + dipstick proteinuria]+[(4?2461021)6
indicator for 3 + dipstick proteinuria]+[(5.1261021)6indicator
for 4 + dipstick proteinuria]+[1?186indicator for occurrence of
vaginal bleeding with abdominal pain]+[(4.2261021)6indicator
for headache and/or visual changes]+[8.47610216indicator for
chest pain and/or dyspnoea].
The model appeared well-calibrated, as shown in the calibration
plot (Figure 1). In all deciles except for the highest the 95%
confidence interval around the observed outcome rate crossed the
diagonal fitted line. The AUC ROC for this model was 0?768
(95% CI 0?735–0?801) (Figure 2) with an average optimism
estimated to be 0.037. Using a cut-off of predicted probability of
25% to define a positive test resulted in a LR of 5.09 [4.12–6.29]
and classified women with 85.5% accuracy (sensitivity 41.4%;
specificity 91.9%). The stratification capacity of the model was
good, as shown by the 784 (37.7%) and 256 (12.3%) women in the
lowest and highest risk groups, respectively (Table 4).
Data from 1,300 women in the fullPIERS cohort were used for
external validation of the developed miniPIERS model. Table 5
presents the results of a comparison of demographics and clinical
characteristics of women in fullPIERS compared to miniPIERS.
The cohorts differed significantly with respect to demographics,
interventions, and pregnancy outcomes. When the miniPIERS
model was applied to the fullPIERS dataset the AUC ROC was
0.713 (95% CI 0.658–0.768) after adjusting the model intercept to
account for differences in the outcome rate between the fullPIERS
and miniPIERS populations (Figure 3).
The results of several sensitivity analyses done using the
miniPIERS cohort are presented in Table 6. In all subsets, model
performance was maintained. Of note, when the cohort was
restricted to only those women admitted with a diagnosis of pre-
eclampsia (defined as hypertension and proteinuria) the AUC
ROC was 0.769 (0.733–0.807). In addition, when including the
whole cohort but restricting the definition of the adverse outcome
to include only maternal death, eclampsia, stroke, cortical
blindness, or retinal detachment the AUC ROC was 0.811
(0.749–0.874). The model performance did not appear to differ
significantly between study regions, although the confidence
interval around the estimate of the AUC ROC in small study
sites was wide (see Table 7).
Table 6 also presents sensitivity analyses performed using the
fullPIERS cohort. Due to the smaller number of events in this
cohort not all analyses could be meaningfully repeated but where
performed, model performance appeared to be maintained.
miniPIERS: HDP Risk Assessment Model for LMICs
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Table 1. Demographics of women in the total cohort comparing women with and without adverse maternal outcomes (N= 2,081).
Characteristic
Women with Adverse
Outcomes (n=401 women)
Women without
Adverse Outcomes
(n=1,680 women) p-Value*
Demographics (within 48 h of eligibility)
Maternal age at EDD (years)
mean (6SD)
27?9 (65?9) 28?5 (66?2) 0?17
Parity $1
n (%)
183 (45?6%) 939 (55?9%) ,0?01
Gestational age at eligibility (wk)
median [interquartile range]
35?3 [30?7–38?1] 37?1 [34?1–38?8] ,0?01
Multiple pregnancy
n (%)
17 (4?2%) 57 (3?4%) 0?41
Smoking in this pregnancy
n (%)
25 (6?2%) 72 (4?3%) 0?08
Pre-eclampsia description
Pre-eclampsia
n (%)
320 (79?8%) 1016 (60?5%) ,0?01
Other HDP
n (%)
81 (20?2%) 664 (39?5%) ,0?01
Clinical measures (within 24 h of eligibility)
Systolic BP
median [interquartile range]
170 [150–186] 150 [140–170] ,0?01
Diastolic BP
median [interquartile range]
110 [100–120] 100 [90–110] ,0?01
Worst dipstick proteinuria
median [interquartile range]
2+ [1+–3+] 1+ [trace–3+] ,0?01
Number of symptoms
median [interquartile range]
1 [0–2] 0 [0–1] ,0?01
Interventions at any time during admission
Corticosteroid administration
n (%)
180 (44?9%) 525 (31?3%) ,0?01
Antihypertensive medications administered
n (%)
386 (96?3%) 1,560 (92?9%) 0?13
MgSO4 administered
n (%)
271 (67?6%) 677 (40?3%) ,0?01
Pregnancy outcomes
Admission-to-delivery interval (all cases) (d)
median [interquartile range]
1 [1–4] 1 [1–5] 0?02
GA on delivery (wk)
median [interquartile range]
35?7 [31?7–38?3] 37?6 [35?3–39?1] ,0?01
Delivery at ,34+0 wk GA
n (%)
160 (39.9%) 290 (17.3%) ,0?01
Cesarean delivery
n (%)
110 (27.4%) 625 (37.2%) ,0?01
Birth weight (g)
median [interquartile range]
2,100 [1,303–2,800] 2,700 [2,000–3,150] ,0?01
Birth weight ,3rd percentile (N babies)
n (%)
64 (16?0%) 284 (16?9%) 0?66
Intrauterine fetal death
($20+0 wk and/or $500 g)
n (%)
54 (13?5%) 94 (5?6%) ,0?01
Neonatal death (before discharge)
n (%)
26 (6?5%) 42 (2?5%) ,0?01
Results for continuous variables presented as mean (6 standard deviation [SD]) when data normally distributed or median [interquartile range] for skewed data.
*p-Values calculated using chi-squared test for categorical variables and Student’s t-test or Mann-Whitney U for continuous variables.
EDD, estimated date of delivery; GA, gestational age.
doi:10.1371/journal.pmed.1001589.t001
miniPIERS: HDP Risk Assessment Model for LMICs
PLOS Medicine | www.plosmedicine.org 5 January 2014 | Volume 11 | Issue 1 | e1001589
Discussion
Using data from a prospectively collected cohort of 2,081
women with HDP admitted to a hospital in five LMICs, we have
developed and internally validated the miniPIERS model. The
final miniPIERS model includes only demographics, symptoms,
and signs that can be measured in primary health care facilities in
low-resourced settings. Data for the study were collected by nurses
and research staff with basic training to ensure the feasibility of
replication of the measurements by comparable workers. For
example, gestational age can be estimated from clinical informa-
tion when ultrasound in unavailable, symptoms can be ascertained
with simple questions, systolic blood pressure can be estimated
easily using the radial pulse, and dipstick proteinuria can be
estimated by assessing the opacity of boiled urine when dipsticks
are not available [23]. By confining ourselves to these simple
measures, the miniPIERS model has potential for use by mid-level
health workers in low-resourced settings. To add to the ease of use
of this model, miniPIERS is being converted to a mobile health
application that will be useable on any mobile device so that health
care workers are not required to calculate risk directly.
Overall, the miniPIERS model performed well on the basis of
accuracy and discrimination ability (i.e., the AUC ROC). There
was a slight underestimation of risk in the highest decile of
predicted probability, but because the model was designed to be
used as a categorical decision rule, this error in calibration is not
thought to be clinically relevant. This model attains similar
stratification, calibration, and classification accuracy as other
established risk scores used in adult and reproductive medicine
[24,25]. To our knowledge, the miniPIERS model is the only
Table 2. Maternal adverse outcomes occurring in the total miniPIERS cohort, outcome counts not mutually exclusive when listed
within 48 hours or at any time during admission.
One or More of Maternal Morbidity or Mortality: Total Cohort (N=2,081)
within 48 h Any Time
Total n (%) 261 (12?5%) 401 (19?3%)
Maternal death 1 2
Central nervous system
Eclampsia ($1) 24 32
Glasgow coma score ,13 8 11
Stroke or reversible ischaemic neurological deficit 3 4
Cortical blindness or retinal detachment 4 5
Posterior reversible encephalopathy 0 1
Cardiorespiratory
Positive inotropic support 2 3
Infusion of a 3rd parenteral antihypertensive 8 9
Myocardial ischaemia/infarction 2 4
SpO2 ,90% 9 22
$50% FiO2 for .1 h 5 7
Intubation (other than for cesarean section) 14 25
Pulmonary oedema 37 51
Haematological
Transfusion of any blood product 129 174
Platelets ,506109/l with no transfusion 15 19
Hepatic
Dysfunction 7 9
Haematoma/rupture 0 0
Renal
Acute renal insufficiency 21 28
Dialysis 1 2
Placental outcomes
Placental abruption 39 70
PPH requiring hysterectomy 39 50
Other adverse events
Severe ascites 26 46
Othera 3 8
Full definitions of all outcomes available at http://pre-empt.cfri.ca/OBJECTIVES/miniPIERS/Reference.aspx.
aIncludes five cases of pulmonary embolism, two cardiac arrests, one ruptured uterus.
SpO2, blood oxygen saturation; FiO2, fractional inspired oxygen; PPH, postpartum haemorrhage.
doi:10.1371/journal.pmed.1001589.t002
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Table 3. Univariate and multivariate analysis of candidate predictors in the miniPIERS cohort.
Candidate Predictor Univariate OR [95% CI] Multivariate OR [95% CI]
Demographics
Maternal age (years) 0.99 [0.97–1.01] n/a
Gestational age at admission (wk) 0.95 [0.92–0.98] 0.34 [0.11–1.11]a
Parity (multiparous versus primiparous) 0.73 [0.57–0.95] 0.74 [0.56–0.99]
Signs
Systolic BP (mmHg) 1.02 [1.01–1.02] 3.89 [1.19–12.66]a
Diastolic BP (mmHg) 1.03 [1.02–1.03] n/a
Dipstick proteinuria
2+ 1.44 [0.99–2.09] 0.80 [0.51–1.27]
3+ 2.88 [2.07–4.00] 1.53 [0.99–2.37]
4+ 3.23 [2.18–4.85] 1.67 [0.96–2.88]
Symptoms
Headache 3.42 [2.58–4.52] 1.53 [1.07–2.17]
Visual disturbances 2.63 [2.00–3.45]
Chest pain 6.42 [3.62–11.37] 2.33 [1.38–3.94]
Dyspnoea 6.35 [4.08–9.89]
Epigastric/right upper quadrant pain 3.93 [2.96–5.21] n/a
Nausea/vomiting 3.40 [2.53–4.57] n/a
Abdominal pain with vaginal bleeding 6.03 [4.25–8.57] 3.24 [2.13–4.94]
Variables presented as part of the multivariate analysis are those that were retained after model development and backward selection.
aLog transformed.
OR, odds ratio.
doi:10.1371/journal.pmed.1001589.t003
Figure 1. Calibration plot of the miniPIERS model applied 2,081 women in the cohort (H–L goodness of fit p=0.1616). Green line
represents line of perfect fit between observed and predicted outcomes and orange line is a smoothed fit line between predicted probability and
mean observed probability in each range.
doi:10.1371/journal.pmed.1001589.g001
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clinical prediction model developed and validated for use with
pregnant women in LMICs.
The miniPIERS model was used to designate women as being
high-risk if their predicted probability of adverse outcome was $
25%. The LR associated with this threshold showed potential
utility as a rule-in test for adverse maternal outcome. By improving
the ability of care providers to identify women at high risk of
adverse outcomes, our specific aim was to reduce triage delays for
women with any HDP in LMICs. What may be most useful is to
set one threshold of predicted probability of adverse outcome, such
as .15%, to initiate increased surveillance and use the higher
threshold of $25% to initiate transport to a facility where
emergency obstetric care is available. The positive predictive value
of the 25% threshold was approximately 40% in all datasets with a
corresponding 85% classification accuracy. These modest results
highlight the fact that demographics, symptoms, and signs alone
will not identify all women with severe disease but still have the
potential to significantly improve care in resource limited areas
and community settings where no or minimal monitoring of
women with the HDP currently occurs.
Figure 2. Receiver operating characteristic curve of the miniPIERS model developed in 2,081 women in the miniPIERS cohort. AUC
0.768 (95% CI 0.735–0.801).
doi:10.1371/journal.pmed.1001589.g002
Table 4. Risk stratification table to assess the miniPIERS prediction model.
Predicted Probability n Event/n in Range Percent Sens Percent Spec Percent PPV Percent NPV LR [95% CI]a
0–5?5% 33/784 — — — — 0.31 [0.22–0.42]
5?6–8?0% 18/286 87.4 41.3 17.6 95.8 0.47 [0.29–0.74]
8?1–15?0% 46/456 80.5 56.0 20.8 95.2 0.78 [0.59–1.03]
15.1–24.9% 56/299 62.8 56.6 29.5 93.6 1.61 [1.24–2.08]
$25% 108/256 41.4 91.9 42.2 91.6 5.09 [4.12–6.29]
Upper limit of predicted probability range used to define a positive test for sensitivity (Sens), specificity (Spec), positive predictive value (PPV), and negative predictive
value (NPV).
aLR for each category calculated using the method described by Deeks et al. [19].
doi:10.1371/journal.pmed.1001589.t004
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There are several limitations to this study. The first is the use of
a combined adverse maternal outcome comprising events of
unequal severity. The Delphi consensus group determined that all
components of the outcome were important enough on their own
to warrant avoidance. The sensitivity analyses performed using a
restricted definition of the adverse maternal outcome demonstrat-
ed that the model maintained its performance even when the more
common and less-severe outcomes were excluded. A second
limitation of the study is the use of broad inclusion criteria that
included women with any HDP. This decision was made to make
the model maximally useful for women who present with HDP,
and for whom the exact diagnosis may not (or cannot) be
determined at the time of clinical presentation. Reassuringly, when
we restricted the cohort to only those women who were admitted
with classically defined pre-eclampsia (hypertension and protein-
uria), model performance was maintained.
A third limitation is the use of a backward elimination method
for final variable selection in the model. Automated variable
Table 5. Demographic table comparing characteristics of women in the development and validation cohorts.
Characteristic
miniPIERS Cohort
(n=2,081 Women)
fullPIERS Cohort (n=1,300
Women) p-Value*
Demographics (within 48 h of eligibility)
Maternal age at EDD (years)
mean (6SD)
28.4 (66.2) 31.7 (66.0) ,0.01
Parity $1
n (%)
1122 (53.9%) 403 (31.0%) ,0.01
Gestational age at eligibility (wk)
median [interquartile range]
36.8 [33.5–38.7] 37.0 [34.1–38.9] 0.04
Pre-eclampsia description
Pre-eclampsia
n (%)
1,336 (64.2%) 1,020 (78.5%) ,0.01
Other HDP
n (%)
745 (35.8%) 280 (21.5%) ,0.01
Clinical measures (within 24 h of eligibility)
Systolic BP
median [interquartile range]
160 [140–170] 166 [155–180] ,0.01
Diastolic BP
median [interquartile range]
100 [95–110] 104 [98–110] 0.22
Worst dipstick proteinuria
median [interquartile range]
2+ [trace–3+] 1+ [trace–3+] 0.01
Number of symptoms
median [interquartile range]
1 [0–1] 1 [0–2] ,0.01
Interventions at any time during admission
Corticosteroid administration
n (%)
705 (33.9%) 337 (25.9%) ,0.01
Antihypertensive medications administered
n (%)
1,946 (93.5%) 836 (64.3%) ,0.01
MgSO4 administered
n (%)
948 (45.5%) 370 (28.5%) ,0.01
Pregnancy outcomes
Admission-to-delivery interval (all cases) (d)
median [interquartile range]
1 [1–4] 1 [1–4] 0.24
GA on delivery (wk)
median [interquartile range]
37.3 [34.6–39.0] 37.6 [35.3–39.1] 0.16
Delivery at ,34 + 0 wk GA
n (%)
450 (21.6%) 319 (24.5%) 0.04
Adverse maternal outcome (within 48 h of admission)
n (%)
261 (12.5%) 84 (6.5%) ,0.01
Birth weight (g)
median [interquartile range]
2,600 [1900–3090] 2,836 [2105–3365] ,0.01
Intrauterine fetal death ($20+0 wk and/or $500 g)
n (%)
148 (7.1%) 15 (1.2%) ,0.01
Neonatal death (before discharge)
n (%)
68 (3.3%) 14 (1.1%) ,0.01
Results for continuous variables presented as mean (6 standard deviation [SD]) when data normally distributed or median (interquartile range) for skewed data.
*p-Values calculated using chi-squared test for categorical variables and Student’s t-test or Mann-Whitney U for continuous variables.
EDD, estimated date of delivery; GA, gestational age.
doi:10.1371/journal.pmed.1001589.t005
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selection methods for model development have been shown to be
sensitive to minor changes in the data and are not easily
reproducible [26]. Ultimately, we felt that creating a simpler
model with only those few variables that were most predictive of
the outcome was important to make application of the model by
minimally trained care providers easier.
Figure 3. Receiver operating characteristic curve of the miniPIERS model applied to the fullPIERS (11) external validation cohort.
AUC 0.713 (95% CI 0.658–0.768).
doi:10.1371/journal.pmed.1001589.g003
Table 6. Results of sensitivity analysis using the miniPIERS model to predict adverse maternal outcome in subsets of the data or to
predict restricted definition of the combined adverse outcome, as described, in the miniPIERS and fullPIERS cohorts.
Cohort Description
Outcome
Incidence in
miniPIERS Cohort
(n/N)
AUC ROC
[95% CI]
Outcome
Incidence in
fullPIERS Cohort
(n/N) AUC ROC [95% CI]
Including only women admitted with diagnosis of pre-eclampsiaa 200/1,336 0.769 [0.733–0.807] 73/1,028 0.723 [0.647–0.793]
Including all but blood transfusion as adverse maternal outcome 174/2,081 0.762 [0.722–0.802] 68/1,300 0.758 [0.732–0.782]
Including all but PPH and placental abruption as adverse
maternal outcome
240/2,081 0.776 [0.742–0.810] n/a n/a
Including maternal mortality, eclampsia, stroke, retinal detachment,
or cortical blindness occurring at any time after admission only
38/2,081 0.811 [0.749–0.874] n/a n/a
Including only women admitted #34+6 wk GA 94/578 0.761 [0.703–0.818] n/a n/a
Including only women admitted .34+6 wk 167/1,503 0.767 [0.723–0.807] 49/973 0.729 [0.636–0.822]
Including only women admitted $37+0 wk GA 108/997 0.780 [0.731–0.829] n/a n/a
aOther hypertensive disorders excluded: chronic hypertension, gestational hypertension without proteinuria, or other adverse conditions, partial HELLP.
GA, gestational age.
doi:10.1371/journal.pmed.1001589.t006
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A fourth limitation is the use of the fullPIERS dataset for
external validation of the model. Although the data were collected
for both fullPIERS and miniPIERS using the same definitions and
protocols, the populations between the two studies differed
significantly, as did the care received. Ideally the model should
be validated in another cohort of data from low-resourced settings
collected by mid-level care providers as part of routine care. This is
planned and would address the possible concern for a reduction in
model performance should these health workers be unable to
maintain the level of measurement accuracy achieved in the
facility data we have used for this study. In the interim, it was
reassuring that there was consistency of results between fullPIERS
and miniPIERS models. miniPIERS model performance was
maintained in the fullPIERS cohort and more importantly
coefficients were similar in overlapping predictors between the
fullPIERS and miniPIERS models. This gives us confidence that
this is a well-defined and stable model. A final limitation is the
inclusion of clinically defined gestational age within the mini-
PIERS model, usually based on last menstrual period dates. As in
fullPIERS, increasing gestational age was associated with dimin-
ishing risk [11]. This inverse relation was maintained in this study
despite the inaccuracy inherent in clinically based gestational age
assessment. Despite these limitations we were able to achieve
accurate predictions from the miniPIERS model.
A major strength of this study is the high quality of data
collected in a standardized manner. We were able to ensure that
complete data were collected in five different LMICs through
careful study monitoring and training of research staff. A second
strength of this study is the generalizability of the resulting model.
By combining high quality data from multiple international sites
we are able to generate a model that should be applicable to any
LMIC setting. The generalizability of the model is further
supported by the results of the region-specific analysis of model
performance. It is likely that we would have had greater predictive
power had we developed the model using a more homogeneous
population from one geographic region, but this would have
resulted in a less generalizable model. By trading some predictive
ability for generalizability, we believe we will have achieved
greater impact on global public health. A final strength of the
study is the use of clinically important timeframes for assessment
and prediction. The miniPIERS model predicted adverse mater-
nal outcomes occurring within 48 hours of assessment using data
from within 24 hours of assessment; such timeframes represent
clinically useful time periods in which transportation or disease-
modifying interventions such as magnesium sulphate, antihyper-
tensive agents, and delivery can be initiated.
When Thaddeus and Maine first proposed the three delay
framework for explaining maternal mortality, they characterised
the first delay as a ‘‘delay in deciding to seek care on the part of the
individual, the family, or both’’ [9]. Factors that have been
identified to influence this decision are the mother’s level of
education and health knowledge, perceived severity of the
complication that is occurring, antenatal care attendance, and
distance to facility [8,9]. An additional barrier to women receiving
quality care for HDP is the global crisis for human resources for
health [6]. We believe that the miniPIERS model represents a
significant step towards overcoming many of these barriers by
providing evidence-based information on disease severity and
allowing task-shifting of monitoring for complications related to
HDP to mid-level health workers.
The potential implications of introduction of this model into
routine antenatal care for LMICs are 2-fold: first, at the individual
level women would not suffer the cost and time away from their
families for unnecessary referrals when safe, increased community
surveillance would be appropriate. Secondly, at the health systems
level, evidence-based monitoring and primary triage for HDPs
(especially pre-eclampsia) is moved from the tertiary facilities alone
into lower level or primary health clinics, thereby increasing the
potential for broad population-based screening, as well as making
more efficient use of already burdened acute care facilities.
We believe that this clinical prediction tool is an important
contribution as it offers the potential to improve health outcomes
of women for a condition that is at the root of a large amount of
morbidity and mortality in the developing world. Nevertheless, as
with any prediction model, its ultimate value will only be
demonstrated with an implementation project that is able to
demonstrate that its potential can be translated to real health
systems change and clinical improvements; such a project, called
the Community Level Interventions for Pre-eclampsia (CLIP)
study (clinicaltrials.gov ID NCT01911494), is presently underway.
For more information on the CLIP study please see http://pre-
empt.cfri.ca/OBJECTIVES/CLIPTrial.aspx). Until that study is
complete, the miniPIERS model can be used as a basis of a
community education programme to increase women’s, families’,
and community-based health workers’ knowledge of warning
symptoms and signs associated with the HDP.
Supporting Information
Dataset S1 Data file containing predicted probability
calculated by the miniPIERS model and observed
outcome for all cases in the miniPIERS and fullPIERS
cohorts.
(XLSX)
Table S1 Table of full definitions of maternal adverse
outcomes used in the miniPIERS study.
(DOCX)
Table 7. Performance of the model in each study site region as a predictor of combined adverse maternal outcome occurring
within 48 hrs of admission.
Region
Contribution of Cases to Total
miniPIERS Cohort (%)
Outcome Incidence in Cohort Used
(n/N) AUC ROC (95% CI)
Brazil 9.0 13/187 0.685 [0.524–0.826]
Fiji 6.1 5/127 0.721 [0.489–0.953]
Pakistan 50.7 157/1,056 0.758 [0.713–0.804]
South Africa 16.8 67/349 0.762 [0.702–0.821]
Uganda 17.4 19/362 0.656 [0.513–0.799]
doi:10.1371/journal.pmed.1001589.t007
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Editors’ Summary
Background. Each year, ten million women develop pre-
eclampsia or a related hypertensive (high blood pressure)
disorder of pregnancy and 76,000 women die as a result.
Globally, hypertensive disorders of pregnancy cause around
12% of maternal deaths—deaths of women during or shortly
after pregnancy. The mildest of these disorders is gestational
hypertension, high blood pressure that develops after 20
weeks of pregnancy. Gestational hypertension does not
usually harm the mother or her unborn child and resolves
after delivery but up to a quarter of women with this
condition develop pre-eclampsia, a combination of hyper-
tension and protein in the urine (proteinuria). Women with
mild pre-eclampsia may not have any symptoms—the
condition is detected during antenatal checks—but more
severe pre-eclampsia can cause headaches, blurred vision,
and other symptoms, and can lead to eclampsia (fits),
multiple organ failure, and death of the mother and/or her
baby. The only ‘‘cure’’ for pre-eclampsia is to deliver the baby
as soon as possible but women are sometimes given
antihypertensive drugs to lower their blood pressure or
magnesium sulfate to prevent seizures.
Why Was This Study Done? Women in low- and middle-
income countries (LMICs) are more likely to develop
complications of pre-eclampsia than women in high-income
countries and most of the deaths associated with hyper-
tensive disorders of pregnancy occur in LMICs. The high
burden of illness and death in LMICs is thought to be
primarily due to delays in triage (the identification of
women who are or may become severely ill and who need
specialist care) and delays in transporting these women to
facilities where they can receive appropriate care. Because
there is a shortage of health care workers who are
adequately trained in the triage of suspected cases of
hypertensive disorders of pregnancy in many LMICs, one
way to improve the situation might be to design a simple
tool to identify women at increased risk of complications or
death from hypertensive disorders of pregnancy. Here, the
researchers develop miniPIERS (Pre-eclampsia Integrated
Estimate of RiSk), a clinical risk prediction model for adverse
outcomes among women with hypertensive disorders of
pregnancy suitable for use in community and primary
health care facilities in LMICs.
What Did the Researchers Do and Find? The researchers
used data on candidate predictors of outcome that are easy
to collect and/or measure in all health care settings and that
are associated with pre-eclampsia from women admitted
with any hypertensive disorder of pregnancy to participating
centers in five LMICs to build a model to predict death or a
serious complication such as organ damage within 48 hours
of admission. The miniPIERS model included parity (whether
the woman had been pregnant before), gestational age
(length of pregnancy), headache/visual disturbances, chest
pain/shortness of breath, vaginal bleeding with abdominal
pain, systolic blood pressure, and proteinuria detected using
a dipstick. The model was well-calibrated (the predicted risk
of adverse outcomes agreed with the observed risk of
adverse outcomes among the study participants), it had a
good discriminatory ability (it could separate women who
had a an adverse outcome from those who did not), and it
designated women as being at high risk (25% or greater
probability of an adverse outcome) with an accuracy of
85.5%. Importantly, external validation using data collected
in fullPIERS, a study that developed a more complex clinical
prediction model based on data from women attending
tertiary hospitals in high-income countries, confirmed the
predictive performance of miniPIERS.
What Do These Findings Mean? These findings indicate
that the miniPIERS model performs reasonably well as a tool
to identify women at increased risk of adverse maternal
outcomes associated with hypertensive disorders of preg-
nancy. Because miniPIERS only includes simple-to-measure
personal characteristics, symptoms, and signs, it could
potentially be used in resource-constrained settings to
identify the women who would benefit most from interven-
tions such as transportation to a higher level of care.
However, further external validation of miniPIERS is needed
using data collected from women living in LMICs before the
model can be used during routine antenatal care. Moreover,
the value of miniPIERS needs to be confirmed in implemen-
tation projects that examine whether its potential translates
into clinical improvements. For now, though, the model
could provide the basis for an education program to increase
the knowledge of women, families, and community health
care workers in LMICs about the signs and symptoms of
hypertensive disorders of pregnancy.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001589.
N The World Health Organization provides guidelines for the
management of hypertensive disorders of pregnancy in
low-resourced settings
N The Maternal and Child Health Integrated Program
provides information on pre-eclampsia and eclampsia
targeted to low-resourced settings along with a tool-kit
for LMIC providers
N The US National Heart, Lung, and Blood Institute provides
information about high blood pressure in pregnancy and a
guide to lowering blood pressure in pregnancy
N The UK National Health Service Choices website provides
information about pre-eclampsia
N The US not-for profit organization Preeclampsia
Foundation provides information about all aspects of
pre-eclampsia; its website includes some personal stories
N The UK charity Healthtalkonline also provides personal
stories about hypertensive disorders of pregnancy
N MedlinePlus provides links to further information about
high blood pressure and pregnancy (in English and
Spanish); the MedlinePlus Encyclopedia has a video
about pre-eclampsia (also in English and Spanish)
N More information about miniPIERS and about fullPIERS is
available
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